Edition:
United States

ZIOPHARM Oncology Inc (ZIOP.OQ)

ZIOP.OQ on NASDAQ Stock Exchange Capital Market

5.11USD
4:00pm EDT
Change (% chg)

$-0.29 (-5.37%)
Prev Close
$5.40
Open
$5.44
Day's High
$5.44
Day's Low
$5.11
Volume
357,840
Avg. Vol
246,076
52-wk High
$7.88
52-wk Low
$4.94

Chart for

About

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies... (more)

Overall

Beta: 1.50
Market Cap(Mil.): $766.60
Shares Outstanding(Mil.): 141.96
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 89.38 16.52
EPS (TTM): -- -- --
ROI: -- 2.39 11.32
ROE: -- 3.35 15.18

BRIEF-Ziopharm Oncology reports Q2 loss per share $0.13

* Ziopharm Oncology reports second quarter 2017 financial results and provides update on recent activities

Jul 31 2017

BRIEF-Ziopharm Oncology announces initiation of stereotactic treatment cohort in phase 1 study of Ad-RTS-hIL-12 + veledimex in recurrent glioblastoma

* Ziopharm Oncology announces initiation of stereotactic treatment cohort in phase 1 study of Ad-RTS-hIL-12 + veledimex in recurrent glioblastoma

Jun 28 2017

BRIEF-CVI Investments reports 6.8 pct passive stake in Ziopharm Oncology

* CVI Investments Inc reports a 6.8 percent passive stake in Ziopharm Oncology Inc as of May 11, 2017 - sec filing Source text - http://bit.ly/2q42eo3 Further company coverage:

May 22 2017

BRIEF-ZIOPHARM announces FDA acceptance of IND for CD33-specific CAR-T cell therapy

* Ziopharm oncology announces fda acceptance of ind for cd33-specific car-t cell therapy targeting relapsed/refractory acute myeloid leukemia

May 02 2017

BRIEF-Ziopharm Oncology reports Q1 loss per share $0.15

* Ziopharm Oncology reports first quarter 2017 financial results and provides update on recent activities

May 01 2017

Earnings vs. Estimates